Spin offs

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and, specifically, in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of new therapeutic strategies based on peptidic protease inhibition. Iproteos is developing peptidic protease inhibitors for the treatment of CNS diseases.

IRB Barcelona Spin offs

Innovation projects

Innovation projects

The Innovation Department is an accredited TECNIO agent in the category of Developers and Technology Enablers.

The TECNIO seal is awarded by the Government of Catalonia, through ACCIÓ, and identifies key technology providers and facilitators in Catalonia. This seal supports the most qualified agents involved in technology transfer; allows companies to access advanced R&D to develop new products and services; increases the scope of technology projects by finding the most suitable technology partners & suppliers; and helps raise competitiveness and technological innovation capacities.

VALUNI 2016 aims to promote the commercialization of projects and technologies by supporting key activities that facilitate the licensing of patents and/or creation of technology-based companies. Two projects promoted by the Innovation Department were awarded in 2017: “Colostage Technology” and “Gate2Brain – transport de molècules al cervell”.

Gínjol is a new patent fund set up by CERCA, an organization belonging to the Government of Catalonia that supervises, supports and facilitates the activities of research centres in Catalonia. IRB Barcelona received funding for the two projects submitted by Innovation Department in the first call for application launched at the end of 2016. Two patents at IRB Barcelona were awarded in the first Gínjol call: “Oncoselective mechanism for gene or viral therapy”, and “A novel and promising new target against Alzheimer’s disease".

News

<p>(Image: Free Illustration. Stem cell sphere)</p>
18 Mai 2017

Avui Josep Corbella, al diari La Vanguardia, dedica un article a l'aposta de Barcelona per la investigació en cèl·lules mare amb aplicacions en medicina regenerati

<p>Chelsea Gerber, for whom the foundation Chelsea’s Hope is named, suffered from Lafora disease (image published in ASBMB).</p>
4 Mai 2017

L'edició de maig de la revista de la S

Testimonial

Contacte

Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193